...
首页> 外文期刊>American Journal of Physiology >Pathways of bradykinin degradation in blood and plasma of normotensive and hypertensive rats.
【24h】

Pathways of bradykinin degradation in blood and plasma of normotensive and hypertensive rats.

机译:血压正常和高血压大鼠血液和血浆中缓激肽降解的途径。

获取原文
获取原文并翻译 | 示例

摘要

Kinins are vasoactive peptide hormones that can confer protection against the development of hypertension. Because their efficacy is greatly influenced by the rate of enzymatic degradation, the activities of various kininases in plasma and blood of spontaneously hypertensive rats (SHR) were compared with those in normotensive Wistar-Kyoto rats (WKY) to identify pathogenic alterations. Either plasma or whole blood was incubated with bradykinin (10 microM). Bradykinin and kinin metabolites were measured by high-performance liquid chromatography. Kininase activities were determined by cumulative inhibition of angiotensin I-converting enzyme (ACE), carboxypeptidase N (CPN), and aminopeptidase P (APP), using selective inhibitors. Plasma of WKY rats degraded bradykinin at a rate of 13.3 +/- 0.94 micromol x min(-1) x l(-1). The enzymes ACE, APP, and CPN represented 92% of this kininase activity, with relative contributions of 52, 25, and 16%, respectively. Inclusion of blood cells at physiological concentrations did not extend the activities of these plasma kininases further. No differences of kinin degradation were found between WKY and SHR. The identical conditions of kinin degradation in WKY and SHR suggest no pathogenic role of kininases in the SHR model of genetic hypertension.
机译:激肽是血管活性肽激素,可以赋予抵抗高血压发展的保护作用。由于其功效很大程度上受酶降解速率的影响,因此将自发性高血压大鼠(SHR)血浆和血液中各种激肽酶的活性与血压正常的Wistar-Kyoto大鼠(WKY)中的激酶活性进行了比较,以确定病原性改变。将血浆或全血与缓激肽(10 microM)一起孵育。缓激肽和激肽代谢物通过高效液相色谱法测定。使用选择性抑制剂通过累积抑制血管紧张素I转换酶(ACE),羧肽酶N(CPN)和氨肽酶P(APP)来确定激肽酶活性。 WKY大鼠的血浆以13.3 +/- 0.94 micromol x min(-1)x l(-1)的速率降解缓激肽。 ACE,APP和CPN酶代表此激肽酶活性的92%,相对贡献分别为52%,25%和16%。以生理浓度包含血细胞不会进一步延长这些血浆激肽酶的活性。在WKY和SHR之间未发现激肽降解的差异。 WKY和SHR中激肽降解的相同条件表明,激肽酶在遗传性高血压SHR模型中没有致病作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号